Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2001

View Archived Issues

Inspire reports progress for two ophthalmic products at ARVO

Cell Genesys discusses highlights for the first quarter of 2001

ARVO 2001 presentations underline promise of squalamine in angiogenic eye diseases

Merger of BioChem Pharma and Shire to close this week

Ajinomoto's novel nucleoside analogue exerts therapeutically useful antiherpesvirus activity

Topical dapsone to be studied for new indication: atopic dermatitis

MGI's lead acylfulvene advances to phase II for refractory sarcoma

Phase I/II results reported for ADA in patients with advanced AIDS

BPI-derived compounds show promise for Rx of pathological retinal neovascularization

TLK-16998: a nonpeptide IR sensitizer effective in mouse models of type 2 diabetes

Enzon begins patient treatment in phase I trial of PEG-paclitaxel

U. of Maryland prepared to begin clinical testing of Multikine for cervical cancer

Potency of several retinoids assessed in bladder cancer cell lines

Lilly's duloxetine reduces symptoms of depression in clinical trials

Abbott presents novel cinnamide-based LFA-1/ICAM-1 antagonist with improved PK properties

Aventis warns of potential liver injury on Arava

Orally active Raf kinase inhibitor from Onyx/Bayer in phase I clinical trials

Avant's oral cholera vaccine shows safety and efficacy in phase IIb trial

Four Amgen products under regulatory review

Large number of D4 antagonists synthesized at Aventis

Eisai presents new acetylcholinesterase-inhibitory piperidines

New series from Ajinomoto with utility in inflammation, cancer, etc.

SB-263831 and related compounds act as caspase inhibitors

Human papillomavirus vaccine patented by Active Biotech

Metastasis-associated antigen discovered at German center

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...